Question 1

What are the benefits of taking Cerebrolysin?

Accepted Answer

The measured benefits are gains on recovery scales in hospital patients, and they are strongest early and in particular groups. A 2024 health technology assessment, which pooled reviews and cost studies, reported gains in neurological function, upper limb movement and recovery of daily activities after acute ischaemic stroke. The same assessment found the clearest gains in patients with moderate to severe stroke. Against that, the 2015 Cochrane review concluded that routine administration to people with acute ischaemic stroke cannot be supported by the available evidence from RCTs. Both can be true. A benefit measured in selected patients on a symptom scale is a different finding from a benefit large and consistent enough to justify giving it to everyone with the condition. The sections below take each outcome separately.

Question 2

Does Cerebrolysin improve memory?

Accepted Answer

In people with dementia, several trials measured better scores on memory and thinking tests. The size of the change is the part to watch. In a 4-week Korean trial of 53 patients with Alzheimer's disease, those given Cerebrolysin improved significantly on the ADAS-Cog, a standard memory and thinking scale, compared with placebo. The 2013 Cochrane vascular dementia review put the pooled gain on the MMSE, a 30-point memory screen, at 1.10 points. A 1991 trial of 60 patients with mild vascular dementia reported better memory, abstract thinking and reaction time on Cerebrolysin. A three-year study of people with early memory loss reported a lower rate of conversion to dementia among those given yearly courses. About one point on a 30-point screen is measurable in a trial and hard to notice in daily life. The three-year study compared treated patients with an untreated group rather than a placebo group, so expectation could explain part of the gap.

Question 3

Does Cerebrolysin increase IQ?

Accepted Answer

No study among the research behind this page measured IQ, and none tested Cerebrolysin in healthy adults. That is where the answer starts, not where it ends. The nearest human result is a 1990 trial in elderly patients with moderate cognitive impairment, where test performance favoured the Cerebrolysin group. In blood cells taken from healthy volunteers, it protected against chemically induced cell death but had no significant effect on cells grown under normal conditions. In ageing mice, it improved short-term memory only in the 12-month-old group. Read that pattern carefully. Where an effect was seen, it was in a brain or cell under damage or decline; where things were normal, the cell study found nothing. That does not establish a ceiling for a healthy person, but it gives no basis for expecting a boost either.

Question 4

What did it do for movement after a stroke?

Accepted Answer

Movement in the arm is where the best-controlled positive result sits. The CARS trial compared Cerebrolysin with a saline drip in stroke patients, and found a large advantage in arm function at day 90 on a standard arm test. When the two CARS trials were pooled as planned, using data from 442 patients, the advantage on that arm test held at day 90. A 70-patient trial in people with severe weakness after stroke found extra motor recovery, and scans showed changes in the brain's main movement pathway. Every one of these patients also had a set rehabilitation programme. So the finding is Cerebrolysin plus rehab against placebo plus rehab, and it says nothing about Cerebrolysin on its own. The CARS authors also called their own study exploratory and small.

Question 5

What did it do for speech after a stroke?

Accepted Answer

One recent randomised trial focused on speech, and it is one of the more carefully designed studies in the field. The ESCAS trial enrolled 132 patients with non-fluent aphasia, difficulty producing speech, after a left-sided stroke, and analysed 123 of them. Both groups had speech therapy, and the Cerebrolysin group showed greater improvements on the Western Aphasia Battery language test. A 2026 Russian-language review drew on that trial to argue that combining speech therapy with Cerebrolysin accelerates recovery of speech. ESCAS was double-blind and placebo-controlled, but it ran in two Romanian centres and its authors called it a pilot needing larger cohorts. One good trial is a signal worth having; it has not been replicated.

Question 6

Who seemed to benefit, and who did not?

Accepted Answer

Severity keeps coming up, in both directions. A 2018 review argued that the effect size of Cerebrolysin was increasing with stroke severity. A nine-trial pooling found a significant shift on the modified Rankin disability scale at day 90 in 314 moderate to severe patients. A re-analysis of the CEREHETIS trial found the effect neutral in patients at low risk of bleeding into the stroke. After clot removal by thrombectomy, 50 selected patients reached independence at 90 days more often than 50 historical controls, 68% against 44%. Subgroup findings are where trials go looking after the main result disappoints, and comparisons against past patients are not randomised. These results say who to study next, not who will benefit.

Question 7

What did it do after a brain injury?

Accepted Answer

The brain-injury studies split by design. The ones without a proper control group look strong, while the randomised one missed its main target. A 2018 meta-analysis found that 112 patients given cerebrolysin had a good Glasgow outcome three times as often as controls. In a 2023 randomised trial with three arms and 93 patients, the main memory and thinking scores showed no statistically significant differences. A 2026 Thai study of 340 patients with moderate injury found 6-month survival of 59.4% against 27.8%. Its own authors warned that because patients were not randomised, the design limits causal inference, meaning what can be said about cause and effect. A survival gap that large, in a study without random allocation, more often reflects who got the drip than what the drip did. The randomised trial, smaller and more careful, is the one that found no main effect.

Question 8

What did it change in Alzheimer's disease, and what not?

Accepted Answer

The Alzheimer's results separate by outcome and by time, and the split is the useful part. A 2015 meta-analysis of six placebo trials found a gain in thinking at 4 weeks. By six months, that cognitive advantage had lost statistical significance. The doctors' overall rating of change, by contrast, stayed better at both 4 weeks and 6 months. The Korean trial found no real change in mood, basic self-care or household tasks against placebo. A 2007 meta-analysis found the overall clinical rating improved in patients after a 4-week course, but said firmer evidence was needed for thinking and daily living. The overall rating is a clinician's judgement. It moved more reliably than the specific tests or the daily-living scores, and those are closer to what a family would notice at home.

Question 9

How fast does Cerebrolysin work?

Accepted Answer

Where trials measured early, differences between the groups appeared within days to weeks of starting a course, and that timing is one of the more consistent features of the whole record. A 60-patient stroke trial found a large advantage over placebo on the NIH Stroke Scale by day 10. The pooled CARS trials found early benefit at day 14 and day 21 on the same scale. In CEREHETIS, stroke scores in patients were lower on day 14, but no difference in disability was observed on day 90. In Alzheimer's disease, a 2002 trial found its global difference at week 12, two months after the 4-week course had ended. Early and fast is the consistent pattern across conditions. Whether an early difference on a symptom scale becomes a lasting difference in disability is the weaker part of the record, and the CEREHETIS result shows the two can separate within a single trial.

Question 10

Do the effects last after the course ends?

Accepted Answer

In dementia, several studies measured after the infusions stopped, and some effects held. A 12-week extension of a vascular dementia pilot found better cognition at the 10-mL and 30-mL doses persisting for at least 12 weeks after treatment cessation. A 2011 Alzheimer's review states that the clinical benefits were largely maintained for several months after ending treatment. In brain injury, a small 2008 study found reduced slowing of the brain's electrical rhythm after one month of treatment and again three months later in patients. The extension study was open-label, meaning patients knew their group by then, and 33 of the original 41 took part. Persistence measured that way is weaker than persistence measured blind.

Question 11

What else has it been tried for in people?

Accepted Answer

A string of single small trials in other nervous-system conditions, each positive on something, none repeated. In motor neurone disease, a 20-patient trial reported a 2.3-point improvement on the ALS functional scale at one month against a 0.9-point decline on placebo. In 40 patients recovering from a multiple sclerosis relapse, disability scores improved in both groups with no significant difference between them. In 192 patients with spinal cord compression in the neck, myelopathy improved in 92% against 52% at one month. A 1997 study in 20 patients with painful diabetic nerve damage reported less pain for at least six weeks. A 2022 report described five older patients whose grey scalp hair darkened during treatment. Each of these is one study, usually small and from one centre. The hair report is five patients with no comparison group. That is a list of leads rather than a list of benefits.

Question 12

What did it do in children?

Accepted Answer

Two trials measured development in young children, both against a group with no injections rather than a placebo. In high-risk premature babies, fewer infants in the Cerebrolysin group failed gross motor development, 33% against 70%. In 60 children aged 3 to 4 with a severe speech disorder, active vocabulary grew by a factor of 3.5 in the Cerebrolysin group. Without a placebo, parents and assessors knew which children had the injections, and young children develop fast on their own. The direction of these results is consistent; the size of them is the part a placebo-controlled trial would need to confirm.

Question 13

Does it help mood or psychiatric conditions?

Accepted Answer

The human evidence is thin, and the authors who looked for it said so. A 2025 scoping review of psychiatry concluded that it could have a relatively small application in that field. The same review suggested some possible role in depression and autism spectrum disorders, and in easing side effects of antipsychotic medicines. A 2023 study of late-onset psychosis grouped it with citicoline, cortexin, actovegin and other add-ons in one group of 23 patients, so its own effect cannot be separated out. In mice given ketamine, it reversed anxiety-like behaviour and memory problems. A mouse model of a psychiatric state is a long way from a person with that condition, and the few human studies that touch on mood were not built to answer the question.

Question 14

What has only been shown in animals?

Accepted Answer

Several of the more striking claims about Cerebrolysin rest on rodent work alone. In a mouse model of an inherited small-vessel brain disease, a nine-week course improved memory and overall health and prolonged lifespan, without changing the disease's typical white-matter damage. In sleep-deprived rats, chronic administration prevented the impairment of short- and long-term memory. In mice after a stroke, daily injections led to full recovery of a grasping task even without rehabilitation training, while stroke size did not change. In a rat model of inflammatory pain, it reduced sensitivity to touch but not the inflammation itself. Lifespan, sleep loss and pain have not been tested as outcomes in people among these sources. An animal result is the reason to run a human trial, not a substitute for one.

Question 15

What do laboratory studies say about how it works?

Accepted Answer

The laboratory work points to nerve-growth signalling and to protection of the blood-brain barrier. A 2022 cell study describes it as enzymatically treated peptides from pig brain that include neurotrophic factors such as BDNF, GDNF, NGF and CNTF, all proteins that support nerve cells. In rats after stroke, it increased new nerve-cell formation, and blocking one growth pathway, PI3K/Akt, abolished that effect. In human brain blood-vessel cells, it reversed the leakiness caused by the clot-busting drug tPA and by fibrin, while a different brain-protein hydrolysate with its own peptide make-up did not. In nerve-like cells starved of oxygen, it acted by switching off GSK3β, an enzyme linked to Alzheimer's disease. These mechanisms explain why trials were run and why some outcomes, like bleeding into a stroke, were chosen. They do not tell you which part of the mixture does the work, or whether these effects happen at the amounts reaching a human brain.

Cerebrolysin: what the research measured